- Home
- BDRX vs TOVX Comparison
BDRX vs TOVX Comparison
Compare BDRX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- TOVX
- Stock Information
- Founded
- BDRX 2000
- TOVX 2001
- Country
- BDRX United Kingdom
- TOVX United States
- Employees
- BDRX N/A
- TOVX N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- TOVX Health Care
- Exchange
- BDRX Nasdaq
- TOVX Nasdaq
- Market Cap
- BDRX 3.8M
- TOVX 4.5M
- IPO Year
- BDRX N/A
- TOVX 2006
- Fundamental
- Price
- BDRX $6.80
- TOVX $0.41
- Analyst Decision
- BDRX
- TOVX Hold
- Analyst Count
- BDRX 0
- TOVX 1
- Target Price
- BDRX N/A
- TOVX N/A
- AVG Volume (30 Days)
- BDRX 53.1K
- TOVX 359.6K
- Earning Date
- BDRX 09-23-2025
- TOVX 11-11-2025
- Dividend Yield
- BDRX N/A
- TOVX N/A
- EPS Growth
- BDRX N/A
- TOVX N/A
- EPS
- BDRX N/A
- TOVX N/A
- Revenue
- BDRX N/A
- TOVX N/A
- Revenue This Year
- BDRX N/A
- TOVX N/A
- Revenue Next Year
- BDRX N/A
- TOVX N/A
- P/E Ratio
- BDRX N/A
- TOVX N/A
- Revenue Growth
- BDRX N/A
- TOVX N/A
- 52 Week Low
- BDRX $5.00
- TOVX $0.37
- 52 Week High
- BDRX $108.90
- TOVX $4.20
- Technical
- Relative Strength Index (RSI)
- BDRX 57.44
- TOVX 47.72
- Support Level
- BDRX $5.81
- TOVX $0.38
- Resistance Level
- BDRX $6.47
- TOVX $0.45
- Average True Range (ATR)
- BDRX 0.50
- TOVX 0.02
- MACD
- BDRX 0.20
- TOVX 0.00
- Stochastic Oscillator
- BDRX 97.30
- TOVX 49.14
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.